home / stock / bcab / bcab articles

BCAB Articles, BioAtla Inc.

Stock Information
Company Name: BioAtla Inc.
Stock Symbol: BCAB
Market: NASDAQ
Website: bioatla.com
Menu
BCAB BCAB Quote BCAB Short BCAB News BCAB Articles BCAB Message Board
Get BCAB Alerts

News, Short Squeeze, Breakout and More Instantly...
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 | Benzinga

SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the developme...
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | Benzinga

Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in pati...

BioAtla to Participate in the Citizens JMP Life Sciences Conference | Benzinga

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the developmen...

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | Benzinga

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the developm...
Shareholder Investigation of BioAtla, Inc. (NASDAQ: BCAB) Announced by Kaskela Law LLC: Investors Encouraged to Contact the Firm | Benzinga

PHILADELPHIA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it has commenced a shareholder investigation into BioAtla, Inc. (...

Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying | Benzinga

The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern ...

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference | Benzinga

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the developme...
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types | Benzinga

Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher dos...

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023 | Benzinga

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the developme...

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit | Benzinga

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the developme...
Next 10